Unapproved peptide ads surge across online platforms

Online listings for unapproved and high-risk peptide products have risen sharply across advertising, eCommerce and social media over the past five years, according to new research from healthcare monitoring firm LegitScript.

The company has published what it describes as a cross-platform dataset covering peptide-related activity from 2020 to 2025. The analysis tracks trends in online adverts, marketplace listings and social media content promoting peptides that fall outside established regulatory frameworks.

LegitScript said the findings show a sustained surge in visibility and availability of problematic peptide products across the commercial internet. The data also indicates that sellers increasingly present these items in ways that obscure their status and intended use.

Sharp rise in ads

The research records the steepest growth in online advertising. LegitScript observed 308% more adverts related to problematic peptides in 2024 than in 2023, and 678% more than in 2022. Early figures for 2025 indicate that activity is likely to exceed 2024 levels.

Marketplace listings have also expanded over the period. The company reported a 276% growth rate in problematic peptide-related products on eCommerce marketplaces over the past five years.

Social media has emerged as a significant channel. LegitScript said it observed 75% more social media content related to problematic peptide sales in 2024 compared with 2023.

The findings highlight a cluster of products that appear most frequently in higher-risk listings. Among hundreds of unauthorised names and terms, LegitScript said Melanotan, BPC-157, TB-500, PT-141 and GLP-1-related compounds were among the most commonly observed.

Peptides are short chains of amino acids. They feature in legitimate medical and research settings, but many of the products flagged in the new analysis fall outside approved therapeutic use and often lack clear quality or safety assurance.

Consumer confusion

LegitScript said the increase in problematic activity mirrors a broader shift in public awareness. Interest in peptides has moved from specialist groups into mainstream wellness, fitness and aesthetic markets.

"Peptides have quickly moved from a niche category into mainstream awareness, and that rise in popularity has been accompanied by a rise in unapproved products entering digital channels," said Gerard Olson, Director of Research at LegitScript. "Our findings confirm this sharp growth across advertising, eCommerce, and social media, making it increasingly important to educate consumers and aid businesses in catching these problematic listings early. Clear visibility into these trends supports business integrity and protects patient safety."

Researchers found that many sellers now operate through professional-looking sites that reference purity testing and laboratory standards. These sites often centre their catalogues on compounds that appeal to consumers seeking aesthetic, performance or recovery outcomes.

Marketing frequently places these products alongside more familiar health-related items. The language can resemble supplement or lifestyle branding, even when the peptide in question is unapproved for general use.

LegitScript said that some merchants describe products as research materials while using imagery and messaging that imply personal use. This framing can blur the distinction between legitimate laboratory applications and consumer-directed use that falls outside regulatory oversight.

The company warned that this environment creates confusion not only for consumers but also for businesses and practitioners. It said that even some healthcare and wellness professionals may not be aware that certain peptides are being promoted and used in ways that are improper and potentially dangerous.

Warning signs

The dataset identifies common red flags linked to high-risk peptide listings. One pattern involves "Not for Human Consumption" or similar disclaimers, where the stated restriction may conflict with the context of the marketing or customer reviews.

LegitScript pointed to minimal or absent buyer qualification steps as another indicator. In many instances, purchases can be completed with no interaction, screening or verification of professional status, despite the nature of the compounds involved.

Catalogues that heavily feature peptides often associated with misuse, including Melanotan or Melanotan II, BPC-157, TB-500 and AOD-9604, may also warrant closer review, according to the research. Supplement-style branding and lifestyle messaging around unapproved products are further signals of potential risk.

Olson said the diversity of business models and product presentations contributes to the difficulty of assessing online peptide offers. "The business models used to market peptides, as well as the peptides themselves, are so varied that both consumers and businesses are easily confused by what is legitimate and what is not," said Olson. "We see everything from 'Research Use Only' language to supplement‐style marketing used to position unapproved treatments as routine. Together, these patterns help explain how certain products surface quickly and how tactics adapt across different parts of the online ecosystem."

Wider enforcement challenge

LegitScript situates the current peptide surge within a broader pattern of online drug trends. The company previously tracked waves of internet activity around GLP-1 medications and erectile dysfunction treatments.

In each case, heightened consumer interest coincided with uneven product quality and an influx of sellers moving faster than enforcement or policy responses. LegitScript said its cross-channel monitoring of adverts, sellers, payments and enforcement actions offers a consolidated view that individual platforms and regulators may not possess.

The firm has produced a Q&A guide that outlines how it categorises peptide products and sets out examples of higher-risk offers and red flags. It has also released a webinar aimed at payment providers and online platforms that want to review their exposure to peptide-related activity.

Scott Roth, Chief Executive of LegitScript, said recent trends fit into a recognisable pattern in digital health commerce. "We're observing peptides follow a pattern we've seen in past online drug booms: rapid consumer interest, uneven product quality, and sellers moving faster than the safeguards meant to protect people," said Roth. "Our role is to provide our customers with the visibility and insight they need to protect their ecosystems and support patient well-being. By combining advanced technology with expert human review, LegitScript empowers organizations to make confident decisions today and stay ahead of tomorrow's emerging threats."